Join to View Full Profile
55 Lake Ave NDepartment Of Hematology/OncologyWorcester, MA 01655
Phone+1 508-856-3933
Are you Dr. Piperdi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bilal Piperdi, MD is an oncologist in Worcester, Massachusetts. He is currently licensed to practice medicine in Massachusetts and New York. He is an Assistant Professor at University Massachusetts Medical School.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2001 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1998 - 2001
Hacettepe University FOMClass of 1997
Certifications & Licensure
NY State Medical License 2011 - 2026
MA State Medical License 2004 - 2012
Publications & Presentations
PubMed
- 24 citationsAssociations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip
JTO Clinical and Research Reports. 2023-01-01 - 4 citationsIndirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael
Immunotherapy. 2022-04-01 - 156 citationsFive Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Radj Gervais
Journal of Thoracic Oncology. 2021-10-01
Press Mentions
An Expert Take on Lung CancerNovember 26th, 2019
